*Department of Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
†Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
‡Department of Medical Oncology/Hematology, Northwell Health Cancer Institute, New Hyde Park, NY
§Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
∥Institute of Cancer Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
¶Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
#Department of Radiation Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
**Loxo Oncology at Lilly, Discovery Technologies, New York, NY
Lyudmyla Demyan, Amber N. Habowski, Dennis Plenker, Daniel A. King: These authors contributed equally to this work
Oliver J. Standring, Caitlin Tsang, Luce St. Surin: These authors contributed equally to this work
Authors Contribution: L.D, D.P, D.A.K, A.N.H, O.J.S, D.A.T, and M.J.W: authors made substantial contributions to conception and design, acquisition of data, analysis, and interpretation of data. Authors participated in drafting the article or revising it critically for important intellectual content; and authors gave final approval of the version to be published. J.M.C, J.B, D.K.D, G. B, D, J.M.H, M.A.T: authors participated in drafting the article or revising it critically for important intellectual content and authors give final approval of the version to be published. S.A.P, H.P, C.T, L.S.S, C.M, P.K.G, S.F, C.V, S.A: authors participated in acquisition of data, analysis, and interpretation of data and participated in drafting the article. D.A.T and M.J.W obtained funding.
This study did not utilize off label drugs.
Organoids predict chemo sensitivity.
Patient-derived organoids (PDOs) can predict response to neoadjuvant chemotherapy in patients with pancreatic cancer. PDO-predicted sensitivity was compared to clinicopathological outcomes in patients in the neoadjuvant setting. PDOs from chemotherapy-naïve and post-NAT tissue enables longitudinal PDO generation to maintain dynamic chemotherapy sensitivity profiling to advance precision medicine in PDAC.
Declaration of Interests: D.A.T. is a member of the Scientific Advisory Board and receives stock options from Leap Therapeutics, Surface Oncology, and Cygnal Therapeutics and Mestag Therapeutics outside the submitted work. D.A.T. is scientific co-founder of Mestag Therapeutics. D.A.T. has received research grant support from Fibrogen, Mestag, and ONO Therapeutics. D.A.T. receives grant funding from the Lustgarten Foundation, the NIH, and the Thompson Foundation.
The authors report no conflicts of interest.
[email protected], [email protected]
